logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca ( AZN ) product Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody ( LAAB ) combination received emergency use authorization ( EUA ) in the US for the pre-exposure...

Read More

December 9, 2021

0

Why Virpax Pharmaceuticals Stock Soared on Two Consecutive Days

Virpax Pharmaceuticals  Virpax Pharmaceuticals ( VRPX ) - a company specializing in developing product candidates for pain management, CNS and anti-viral indications, announced the receipt of a written pre-investigational new drug ( pre-IND ) response from the U.S. Food and Drug...

Read More

August 18, 2021

0

Arcturus Therapeutics Additional Updates from ARCT-154 and ARCT-165 Clinical Trials and More

Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings ( ARCT ) is a clinical-stage mRNA medicines company of enabling technologies with an interesting pipeline of treatments and vaccines as well as other products for diseases that have yet to find treatments. Arcturus Therapeutics’...

Read More

December 16, 2021

0

Compugen Has Encouraging News

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen ( CGEN ) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with...

Read More

September 8, 2020

0

Axsome Therapeutics: Treating Major Depressive Disorder. Vivos Therapeutics: Improving the Treatment of Obstructive Sleep Apnea

Axsome Therapeutics Inc and Major Depressive Disorder In a teleconference on August 20, 2021, the U.S. Food and Drug Administration ( FDA ) informed Axsome Therapeutics ( AXSM ) that its review of the new drug application ( NDA )...

Read More

August 23, 2021

0

Gilead Sciences and Arcus Biosciences: Complete Closing of Option Exercises of 3 Programs. See Also: HOLD Put on Lenacapavir Due to Vial Quality Concern

Gilead Sciences and Arcus Biosciences Gilead Sciences ( GILD ) and Arcus Biosciences ( RCUS ) announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies. On...

Read More

December 22, 2021

0

Cassava Sciences Issued a Response to Claims Posted After Market Yesterday. See Also: Cassava Sciences Good News

Cassava Sciences Responds to Misleading Posts Cassava Sciences ( SAVA ) today issued a response to claims that were posted online yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and...

Read More

August 25, 2021

0

Cassava Sciences Promising and Encouraging Results of Its Alzheimer's Disease Product Sumifilam

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers that our positive opinion about Cassava Sciences' product created and developed for Alzheimer’s disease happens to be right. Cassava Sciences ( SAVA ) announced today...

Read More

September 14, 2020

0

Seattle Genetics: Two New Oncology Collaborations with Merck

Seattle Genetics Two New Strategic Oncology Collaborations with Merck Seattle Genetics ( SGEN ) and Merck ( MRK ) , known as MSD outside the United States and Canada, announced today two new strategic oncology collaborations. The companies will globally...

Read More

September 14, 2020

0

Positive News for TCR2 Therapeutics - The U.S. FDA Granted Orphan Drug Designation to Gavo-Cel for Cholangiocarcinoma

TCR2 Therapeutics TCR2 Therapeutics ( TCRR )  is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor ( TCR ) Fusion Construct T cells (TRuC®-T cells)...

Read More

September 2, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 123
  • 124
  • 125
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy